<DOC>
	<DOCNO>NCT01216371</DOCNO>
	<brief_summary>The aim ist identify biomarkers blood , indicate early response early treatment resistance .</brief_summary>
	<brief_title>Resection Pulmonary Metastasis Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy ( SMAT )</brief_title>
	<detailed_description>Prospective randomize multi-center Phase II trial resection metastases pulmonary metastasis ( poor prognosis ) clear cell renal cell carcinoma + / - adjuvant sunitinib therapy one year</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>&gt; /= 2 synchronous within 24 Months Nephrectomy occur pulmonary metastasis . Patients back 2 year solitary lung metastasis , bone metastasis brain metastasis resect , may also include study . Aged 18 75 year functionally acceptable surgical risk Women conceptional age : negative pregnancy test adequate contraception Adequate hematologic , renal , hepatic coagulationphysiological function Amylase/ Lipase &lt; 1,5 x upper limit normal Informing patient study present write consent participate clarification accordance stipulation AMG ( german drug law ) , principle GCP ( `` inform consent '' ) Patient compliance geographic proximity allow adequate followup Presence metastasis outside lung progress 12week sunitinib therapy resection metastasis R1 R2finding resection metastasis Dialysis nephrectomy Previous exist serious cardiovascular ( grade III IV accord NYHA ( New York Heart Association ) ) disease , active angina pectoris ischemia , myocardial infarction within previous 6 month , uncontrolled hypertension ( RR diastolic 120 mmHg ( Millimeters mercury ) ) serious hematopoetic ( e.g . serious Bone marrow aplasia ) , pulmonary , hepatic renal Disease Stroke within previous six month Patients poorly control diabetes mellitus Serious bacterial fungal infection chronic hepatitis B C , HIV ( human immunodeficiency virus ) infection autoimmune disease prior organ transplantation prior autologous bone marrow transplant stem cell transfer within last 4 month study Neuropsychiatric disease affect patient compliance Manifesto , second malignancy malignancy within past 5 year ( except basal cell carcinoma , carcinoma situ cervix , incidental prostate carcinoma , superficial urothelial Ca pTaG12 pT1G1 ) Therapy immunotherapeutic agent include monoclonal antibody , cytotoxic drug hormone ( bisphosphonates oral contraceptive ) within last 4 week prior enrollment . Previous use inhibitor Ras/Raf , MEK kinase , AKT kinase mTOR inhibitor induction Farnesyltransferase Previous use angiogenesis inhibitor VEGF / VEGFR , PDGF / PDGFR key molecule angiogenesis parallel treatment rifampicin Participation treatment study last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>carcinoma</keyword>
	<keyword>metastasis</keyword>
	<keyword>renal</keyword>
	<keyword>lung</keyword>
</DOC>